Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by Pyxis Oncology, Inc. on June 11, 2024. The meeting was conducted virtually via live audio webcast. As of the record date of April 18, 2024, there were 58,876,390 shares of common stock outstanding entitled to vote.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and voting results.
Material Changes and Voting Results
A quorum was established with 42,336,191 shares present. Stockholders acted on two proposals:
- Proposal One: Election of Directors
- Dr. Santhosh Palani, Ph.D., CFA (Class I): Elected with 28,241,400 votes For, 93,674 Withheld, and 14,001,117 Broker Non-Votes.
- Mr. John Flavin (Class III): Elected with 21,045,395 votes For, 7,287,768 Withheld, and 14,003,028 Broker Non-Votes.
- Dr. Lara Sullivan, M.D. (Class III): Elected with 24,369,861 votes For, 3,963,302 Withheld, and 14,003,028 Broker Non-Votes.
- Dr. Jakob Dupont, M.D. (Class III): Elected with 28,220,452 votes For, 114,622 Withheld, and 14,001,117 Broker Non-Votes.
- Proposal Two: Ratification of Auditors
- Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
- Votes: 42,153,375 For, 151,087 Against, 31,729 Abstain, and 0 Broker Non-Votes.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the tenure of the newly elected directors (Class I until 2025; Class III until 2027).
- Confirm the significant number of broker non-votes (approx. 14 million) on director elections, which may indicate limitations in proxy voting instructions.
- Review the high number of "Withheld" votes for Mr. John Flavin (7.2 million) compared to other nominees.
- Confirm the ratification of Ernst & Young LLP for the 2024 fiscal year.